Biotechnology

GELITA & Geltor Sign Letter of Intent to Commercialize First Animal-Free Biodesigned Collagen for Dietary Supplements, a Market with Huge Growth Potential

LAS VEGAS, Oct. 17, 2019 /PRNewswire/ -- In the halls of the SupplySide West (SSW) Expo, officials from both GELITA and Geltor signed a letter of intent for developing, producing and marketing the first ingestible animal-free collagen proteins – to be launched in late 2020. In this arrangement, G...

2019-10-17 18:32 134

MetGen Earns Acclaim from Frost & Sullivan for its Unique, Customized Enzyme Technologies, METNIN™ and ENZINE®

The technologies solve the industry's major pain points regarding the valorization of lignin, shorter technology development cycles, and customization of enzymes for different applications LONDON, Oct. 17, 2019 /PRNewswire/ -- Based on its recent analysis of the European industrial enzymes marke...

2019-10-17 15:00 153

Curiox Biosystems Achieves Commercialisation and Fund Raising Success in North Asia with the Support of Cornerstone Investor, ZIG Ventures

* CURIOX BIOSYSTEMS, is an A*STAR spinoff company, that develops bioinstrumentation solutions used in cell analysis and therapy for the pharmaceutical and biotech industries. The company has successfully penetrated theUSA, PRC, Korean and European markets and also secured a Series B funding of ...

2019-10-16 07:00 324

Celemics Expedites Target Enrichment NGS Data Insights by Partnering With BlueBee on a Global Genomics Data Solution

SEOUL, South Korea, and RIJSWIJK, The Netherlands, Oct. 15, 2019 /PRNewswire/ -- Celemics, provider of NGS target enrichment kits and innovative sequencing platforms, announced today the release of a comprehensive NGS target enrichment workflow for clinical and translational research applications...

2019-10-15 19:00 303

CTFH and Insilico Medicine Enter Al Drug Discovery Collaboration Focused On Accelerating First-in-Class Therapeutics, Worth Up to $200 million

HONG KONG and NANJING, China, Oct. 9, 2019 /PRNewswire/ -- Insilico Medicine, a company developing an end-to-end drug discovery pipeline utilizing the latest advances in deep learning, has entered into a two-program AI drug discovery collaboration agreement with Jiangsu Chia Tai Fenghai Pharmaceu...

2019-10-09 20:58 456

Datar Cancer Genetics Announces Positive Results With 42.9% Objective Response Rate, and 90.5% Disease Control Rate in Heavily Pre-treated Patients With Ultra-personalised Pan-cancer Treatment Protocol in the RESILIENT Trial

LONDON, MUMBAI, India and BAYREUTH, Germany, Oct. 9, 2019 /PRNewswire/ -- - RESILIENT Protocol captures Encyclopedic information from tumors and uses Artificial Intelligence (AI) to optimize treatments; - Objective Response and Disease Control Comparable to or better than most Immunotherapy opti...

2019-10-09 17:56 752

Ascletis Appoints Former Novartis Global Head Dr. Handan He as Chief Scientific Officer

HANGZHOU, China and SHAOXING, China, Oct. 8, 2019 /PRNewswire/ -- Ascletis Pharma Inc. (1672.HK), an innovative R&D driven, commercial-stage biotechnology company addressing unmet medical needs in therapeutic areas including anti-viral, cancer and fatty liver diseases, announces today that Dr.Han...

2019-10-08 08:00 439

Cross-industrial technologies make a splash in Asia Agri-Tech Expo in Taipei

TAIPEI, Oct. 5, 2019 /PRNewswire/ -- The Asia Agri-Tech Expo & Forum 2019 will take place at Taipei Nangang Exhibition Center Hall 1 fromOctober 31 to November 2. Organised by Informa Markets of Taiwan Office (UBM Taiwan), the tradeshow features innovative, eco-friendly and sustainable manufac...

2019-10-05 10:06 167

AGC Biologics Appoints New Site Head/General Manager of Copenhagen, Denmark Operations

Jeffrey D. Mowery Named Site Head/General Manager BOTHELL, Washington, Oct. 1, 2019 /PRNewswire/ -- AGC Biologics, a global leader in clinical and commercial manufacturing of therapeutic proteins, announced today the appointment ofJeffery D. Mowery as Site Head/General Manager of theCopenhagen,...

2019-10-01 07:00 344

Interleukin 11 Identified as New Therapeutic Target for Idiopathic Pulmonary Fibrosis

* Idiopathic pulmonary fibrosis (IPF) is a severe and fatal disease that causes lung damage and scarring * Blocking a protein called interleukin-11 (IL11), which is abnormally high in the lungs of patients with IPF, can reverse lung fibrosis and scarring in preclinical studies * Enleofen Bi...

2019-09-30 15:00 200

Preclincal Results of Baoyuan's Next-Generation ROS1/NTRK Inhibitor AB-106 Published in Nature Communications

HANGZHOU, China, Sept. 25, 2019 /PRNewswire/ -- The preclinical results of AB-106 (original code: DS-6051b), an investigational next generation ROS1/NTRK dual inhibitor exclusively in-licensed by AnHeart Therapeutics, a wholly-owned subsidiary of Baoyuan Biopharmaceuticals Technology (Hangzhou) C...

2019-09-25 18:44 707

AGC Biologics Appoints New Site Head/General Manager of Chiba, Japan Operations

Naofumi Kagami Named Site Head/General Manager  BOTHELL, Washington, Sept. 25, 2019 /PRNewswire/ -- AGC Biologics, a global leader in clinical and commercial manufacturing of therapeutic proteins, announced today the appointment ofNaofumi Kagami as Site Head/General Manager of theChiba, Japan fa...

2019-09-25 01:42 1045

Supply Chain Digitization Creates New Revenue Opportunities in the Vaccine Market

High investment in adult immunization and innovations in DNA vaccines will rejuvenate the vaccines market, finds Frost & Sullivan SANTA CLARA, California, Sept. 24, 2019 /PRNewswire/ -- The need for improved immunogenicity, delivery technologies and reliable supply are driving the shift from the...

2019-09-24 23:28 1044

binx health Announces First Patients Benefiting From Single-Visit Test and Treatment for Chlamydia and Gonorrhea

binx FDA-cleared platform already impacting human health-poised to transform care for millions BOSTON, Sept. 23, 2019 /PRNewswire/ -- binx health, the pioneer in anywhere, anytime testing for women's health, today announced the first real-world use of the binxio platform, delivering same-visit d...

2019-09-23 20:30 890

2019 CSCO| CStone announces promising ORR, anti-tumor activity and safety data with its anti-PD-L1 antibody CS1001 in MSI-H/dMMR solid tumors

SUZHOU, China, Sept. 22, 2019 /PRNewswire/ -- CStone Pharmaceuticals ("CStone" or the "Company", HKEX: 2616) today announced results from the microsatellite instability high/deficient mismatch repair (MSI-H/dMMR) solid tumor cohort in the GEMSTONE-101 Phase Ib study of the Company's investigation...

2019-09-22 14:22 779

2019 CSCO | CStone announces preliminary results from Phase I trial of CS1002 demonstrating characteristics comparable to ipilimumab

SUZHOU, China, Sept. 22, 2019 /PRNewswire/ -- CStone Pharmaceuticals ("CStone" or the "Company", HKEX: 2616) today announced preliminary results from the Phase Ia trial of the Company's anti-CTLA-4 antibody in an oral presentation at the 22nd Annual Meeting of the Chinese Society of Clinical Onco...

2019-09-22 13:39 929

Global Cord Blood Corporation to Hold Annual General Meeting in Hong Kong on December 5, 2019

HONG KONG, Sept. 20, 2019 /PRNewswire/ -- Global Cord Blood Corporation (NYSE: CO) ("GCBC" or the "Company"),China's leading provider of cord blood collection, laboratory testing, hematopoietic stem cell processing, and stem cell storage services, today announced that the Company will hold its 20...

2019-09-20 19:00 11296

Advanced Aesthetic Technologies and China National Biotec Group Announce Strategic Cooperation

BROOKLINE, Massachusetts, Sept. 19, 2019 /PRNewswire/ -- Advanced Aesthetic Technologies, Inc. (AAT), a leader in aesthetic gel implant technology, and China National Biotec Group (CNBG), a subsidiary of China National Pharmaceutical Group Corporation (SINOPHARM) today announced the execution of ...

2019-09-19 23:12 1352

Taiwan Medical Professionals Assisting Malaysian Patients Rediscover Their Confidence and Rediscover Life

KUALA LUMPUR, Malaysia, Sept. 19, 2019 /PRNewswire/ -- Taiwan's medical care is renowned for its high quality, advanced technology, professionalism and affordable pricing. In fact, the cost of medical treatment inTaiwan is typically one-fifth of comparable services inEurope and the US. To further...

2019-09-19 14:05 1117

Inovio Receives NIH Funding to Target its dMAb® Technology Against Antimicrobial-Resistant Infection

PLYMOUTH MEETING, Pennsylvania, Sept. 17, 2019 /PRNewswire/ -- Inovio Pharmaceuticals, Inc. (NASDAQ: INO) announced today that the company and its collaborator The Wistar Institute have received a$4.6 million National Institutes of Health (NIH) grant in support of innovative research to tackle a...

2019-09-17 21:00 1325
12345 ... 51